AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03470259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Fluorescence Reflectance Imaging
Description: A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.
Study NCT03470259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectroscopy
Description: A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.
Study NCT03731897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.
Description: Plantar fascia will be injected to the places where it adheres to the bone.
Study NCT03731897 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 9 cc salin + 1cc 2% lidocaine.
Description: Plantar fascia will be injected to the places where it adheres to the bone.
Study NCT02847039 — intervention group
Intervention type: GENETIC
Intervention: Blood samples
Description: Blood samples at baseline.
Study NCT04176731 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Horizon™ Automated Glucose Control System
Description: The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
Study NCT02389764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: Initial dose is 200 mg twice daily orally for a 28 day cycle.
Study NCT02389764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
Study NCT04518046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
Study NCT04518046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Study NCT04518046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
Study NCT01424605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DLT intubation
Description: Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
Study NCT00276198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.
Study NCT00276198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferripel-3, Vitamins A&D drops
Description: Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
Study NCT01549834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: Low Dose
Study NCT00385827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
Study NCT00385827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily
Study NCT00385827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg orally twice daily
Study NCT04028791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise on ergocycle
Description: The exercise includes 15 minutes of warm up, then participants will be asked to pedal as fast as possible for 6 seconds. The test of 6 seconds will be repeated twice or more with recovery each time
Study NCT02375425 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention-specimen collection study only
Study NCT01156909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period.
Study NCT03817099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention based on My Dia-RNP
Description: Subjects in this group will be advised to follow My Dia-RNP and to incorporate diabetes-specific formula (Nutren®Untuk Diabetik)
Study NCT03817099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects in the group continue with the usual care
Study NCT02357056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wet Lab
Description: ITA dissection and Annuloplasty Sutures in porcine model.
Study NCT02357056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Lab
Description: Camera and clutching, peg transferring, intracorporeal knot tying
Study NCT02357056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: daVinci Surgical Skills simulation
Study NCT01238341 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Description: An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
Study NCT01589588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open Hudson Mask
Description: Mask type 1 oxygen
Study NCT01589588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cluster headache mask with 3 L reservoir
Description: Mask type 2 with oxygen
Study NCT01589588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mask 3
Description: Mask type 3 oxygen
Study NCT01589588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carnét oxygen demand valve
Description: mask type 3 oxygen
Study NCT01589588 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Carnét oxygen demand valve
Description: mask type 3 placebo
Study NCT04690335 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MV-012-968
Description: MV-012-968 is a recombinant, live attenuated RSV vaccine.
Study NCT04690335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT02117219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 Evaluate MEDI4736 in MDS
Description: MEDI4736 will be administered by IV infusion
Study NCT02117219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIDAZA
Description: VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
Study NCT02117219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: tremelimumab will be administered by IV infusion
Study NCT03300414 — intervention group
Intervention type: OTHER
Intervention: One time blood draw
Description: Same as part 1
Study NCT06019026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri-Lock
Description: Implant Stem
Study NCT06019026 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Summit
Description: Implant Stem
Study NCT03612479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDFIT Healthy
Description: The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.
Study NCT03612479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KIDFIT Safe
Description: The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
Study NCT01393418 — intervention group
Intervention type: OTHER
Intervention: Cardiac Surgery
Study NCT01549834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: High Dose
Study NCT01549834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study NCT00780559 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Diet and Physical Activity
Description: Subjects will receive an individually tailored diet and physical activity enhancement program
Study NCT00780559 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
Study NCT03362385 — intervention group
Intervention type: OTHER
Intervention: Patients with OSA based on sleep study
Description: Polysomnography or Polygraphy
Study NCT03362385 — intervention group
Intervention type: OTHER
Intervention: Patients without OSA based on sleep study
Description: Polysomnography or Polygraphy
Study NCT01495572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 IV (in the vein) for 5 days (day -5 to -1)
Study NCT01495572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV (in the vein) for days -7 and -6
Study NCT01495572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
Study NCT01495572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MART-1 Reactive CD8+ PBL
Description: Intravenous (IV) over 30 minutes on day 0
Study NCT04577053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scientific Consciousness Interface Operations (SCIO) Class II FDA approved medical device
Description: Manufactured by QX World Ltd. in Budapest, Hungary
Study NCT00312598 — intervention group
Intervention type: DRUG
Intervention: Aripiprazole
Study NCT01327846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT01327846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01327846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
Study NCT01327846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
Study NCT02623751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2375
Description: KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily.
Study NCT02623751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally administered once daily.
Study NCT02784964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elixcyte 8 ml
Description: ADSC 6.4\*10\^7 cells, allogeneic injection
Study NCT02784964 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hya Joint Plus
Description: Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
Study NCT02784964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elixcyte 4 ml
Description: ADSC 3.2\*10\^7 cells, allogeneic injection
Study NCT02784964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elixcyte 2 ml
Description: ADSC 1.6\*10\^7 cells, allogeneic injection
Study NCT01262547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabrasion-Micrografting
Description: Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).
Study NCT01262547 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: Only dermabrasion (removal of epidermis) alone will be done at baseline.
Study NCT00636740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 20mg Tablets
Description: Oral enteric coated tablets, 20mg, weekly, 8 weeks
Study NCT00636740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
Study NCT00636740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 20mg Tablets
Description: Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
Study NCT01888549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose PPI
Description: :40mg, po(per oral) 2times.day, 8weeks
Study NCT01888549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard PPI
Description: : 40mg, po(per oral) 1times.day, 8weeks
Study NCT01888549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01064700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Litebook Bright Light Box
Description: Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
Study NCT01064700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Litebook inactivated negation ion generator (the placebo)
Description: Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
Study NCT02919553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified wet-suction technique
Description: Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.
Study NCT02919553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capillary slow pull technique
Description: The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
Study NCT04033965 — intervention group
Intervention type: GENETIC
Intervention: Corellation of Mutations, TILs and Age in Breast Cancer
Study NCT03742375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV genotyping
Description: Quantitative HPV genotyping on anal swab
Study NCT00735280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: bolus of 100 U/kg of unfractionated heparin
Study NCT03507907 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization for Study Group
Description: Mulligan Mobilization techniques were applied to the older adults who included in study group.
Study NCT03507907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional therapy for Control Group
Description: Conventional therapy was applied to the older adults who included in control group.
Study NCT04310293 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Femara,Grotwth hormone,HMG
Description: NOVEL THERAPY
Study NCT02844270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Description: Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Study NCT02487043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A telephone-based case-management intervention
Description: Regular Telephone support delivered by Health coaches
Study NCT01462006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: randomized to drug or placebo, followed by washout, followed by crossover
Study NCT01462006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: randomized to drug or placebo, followed by washout, followed by crossover
Study NCT02963662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass was one of the interventions pre-specified to be administered to participants. The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
Study NCT02963662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy was the other intervention pre-specified to be administered to participants. The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
Study NCT02097589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
Study NCT02097589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumovax 23
Description: Pneumovax 23 injected once, intramuscularly at Day 7.
Study NCT02097589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumovax 23
Description: Pneumovax 23 injected once, intramuscularly at Day 7.
Study NCT02097589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (lactose pill)
Description: 10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
Study NCT02112409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cell salvage technique
Description: blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
Study NCT02112409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cell salvage technique
Description: blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
Study NCT02112409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acute normovolemic hemodilution
Description: Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
Study NCT00481364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 40 mg/day
Study NCT00481364 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 tb/day
Study NCT00574691 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 7F Ensure Medical Vascular Closure Device
Description: Vascular Closure Device
Study NCT05731752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX009
Description: The subjects will receive HX009 treatment via IV infusion once every 2 weeks at different dose escalation cohorts
Study NCT04209907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retrolaminar block tecnique
Description: By using ultrasound probe, the needle with in-plane , after seeing vertebral lamina, the local anesthetic will injectate
Study NCT01471444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3.
Study NCT01471444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
Study NCT01471444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
Study NCT01471444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete.
Study NCT01471444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.